Switch theme
Sign up to access all valuation multiples
UroGen Pharma Ltd is a clinical-stage biotechnology firm specializing in solutions for urothelial and specialty cancers. The company has developed RTGel reverse-thermal hydrogel, a proprietary technology enhancing the therapeutic profiles of existing drugs by enabling sustained release. Their flagship product, Jelmyto (mitomycin) for pyelocalyceal solution, along with investigational candidate UGN-102 (mitomycin) for intravesical solution, targets non-surgical tumor ablation in forms of non-muscle invasive urothelial cancer. Additionally, their immuno-uro-oncology pipeline includes UGN-301 (zalifrelimab), an anti-CTLA-4 antibody, intended for both monotherapy and combination therapy. Revenue is generated from product sales.
2004
235
LTM Revenue $99.3M
LTM EBITDA -$102M
$375M
Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.
UroGen Pharma has a last 12-month revenue of $99.3M and a last 12-month EBITDA of -$102M.
In the most recent fiscal year, UroGen Pharma achieved revenue of $90.4M and an EBITDA of -$110M.
UroGen Pharma expects next 12-month revenue of XXX and NTM EBITDA of XXX
See UroGen Pharma valuation multiples based on analyst estimates| FY 2023 | FY 2024 | FY 2025 | LTM | NTM | |
|---|---|---|---|---|---|
| Revenue | $82.7M | $90.4M | XXX | XXX | XXX |
| Gross Profit | $56.7M | $73.4M | XXX | XXX | XXX |
| Gross Margin | 69% | 81% | XXX | XXX | XXX |
| EBITDA | -$81.9M | -$110M | XXX | XXX | XXX |
| EBITDA Margin | -99% | -122% | XXX | XXX | XXX |
| Net Profit | -$110M | -$102M | XXX | XXX | XXX |
| Net Margin | -133% | -113% | XXX | XXX | XXX |
| Net Debt | $42.1M | $3.5M | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
As of April 15, 2025, UroGen Pharma's stock price is $11.
UroGen Pharma has current market cap of $489M, and EV of $375M.
See UroGen Pharma trading valuation data| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $375M | $489M | XXX | XXX | XXX | XXX | $-2.94 |
Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more
Sign UpAs of April 15, 2025, UroGen Pharma has market cap of $489M and EV of $375M.
UroGen Pharma's trades at 3.8x LTM EV/Revenue multiple, and -3.7x LTM EBITDA.
Analysts estimate UroGen Pharma's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
See valuation multiples for UroGen Pharma and 10K+ public comps| FY 2024 | FY 2025E | FY 2026E | FY 2027E | |
|---|---|---|---|---|
| EV | $375M | XXX | XXX | XXX |
| EV/Revenue | 4.2x | XXX | XXX | XXX |
| EV/EBITDA | -3.4x | XXX | XXX | XXX |
| P/E | -3.9x | XXX | XXX | XXX |
| P/E/Growth | n/a | XXX | XXX | XXX |
| EV/FCF | -3.9x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.
Sign UpUroGen Pharma's NTM/LTM revenue growth is 64%
UroGen Pharma's revenue per employee for the last fiscal year averaged $0.4M, while opex per employee averaged $0.8M for the same period.
Over next 12 months, UroGen Pharma's ratio of sales and marketing spend to revenue is estimated to be XXX , while its R&D spend to revenue to be XXX .
Analysts estimate UroGen Pharma's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
See operational valuation multiples for UroGen Pharma and other 10K+ public comps| FY 2024 | NTM | FY 2025E | FY 2026E | FY 2027E | |
|---|---|---|---|---|---|
| Revenue Growth | 9% | XXX | XXX | XXX | XXX |
| EBITDA Margin | -122% | XXX | XXX | XXX | XXX |
| EBITDA Growth | 35% | XXX | XXX | XXX | XXX |
| Rule of 40 (SaaS-only) | -58% | XXX | XXX | XXX | XXX |
| Revenue per Employee | $0.4M | XXX | XXX | XXX | XXX |
| Opex per Employee | $0.8M | XXX | XXX | XXX | XXX |
| S&M Expenses to Revenue | n/a | XXX | XXX | XXX | XXX |
| G&A Expenses to Revenue | n/a | XXX | XXX | XXX | XXX |
| R&D Expenses to Revenue | 63% | XXX | XXX | XXX | XXX |
| Opex to Revenue | 197% | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| 2025E | 2026E | 2027E | 2025E | 2026E | 2027E | |
| Julphar | XXX | XXX | XXX | XXX | XXX | XXX |
| Benevolent AI | XXX | XXX | XXX | XXX | XXX | XXX |
| Galapagos | XXX | XXX | XXX | XXX | XXX | XXX |
| Pharming | XXX | XXX | XXX | XXX | XXX | XXX |
| Vivoryon Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
UroGen Pharma acquired XXX companies to date.
Last acquisition by UroGen Pharma was XXXXXXXX, XXXXX XXXXX XXXXXX . UroGen Pharma acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX ).
See M&A valuation multiples| Acquired Company | EV | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.
Sign Up| When was UroGen Pharma founded? | UroGen Pharma was founded in 2004. |
| Where is UroGen Pharma headquartered? | UroGen Pharma is headquartered in United States of America. |
| How many employees does UroGen Pharma have? | As of today, UroGen Pharma has 235 employees. |
| Who is the CEO of UroGen Pharma? | UroGen Pharma's CEO is Ms. Elizabeth Barrett. |
| Is UroGen Pharma publicy listed? | Yes, UroGen Pharma is a public company listed on NAS. |
| What is the stock symbol of UroGen Pharma? | UroGen Pharma trades under URGN ticker. |
| When did UroGen Pharma go public? | UroGen Pharma went public in 2017. |
| Who are competitors of UroGen Pharma? | Similar companies to UroGen Pharma include e.g. Julphar, Benevolent AI, Galapagos, Pharming. |
| What is the current market cap of UroGen Pharma? | UroGen Pharma's current market cap is $489M |
| What is the current revenue of UroGen Pharma? | UroGen Pharma's last 12-month revenue is $99.3M. |
| What is the current EBITDA of UroGen Pharma? | UroGen Pharma's last 12-month EBITDA is -$102M. |
| What is the current EV/Revenue multiple of UroGen Pharma? | Current revenue multiple of UroGen Pharma is 3.8x. |
| What is the current EV/EBITDA multiple of UroGen Pharma? | Current EBITDA multiple of UroGen Pharma is -3.7x. |
| What is the current revenue growth of UroGen Pharma? | UroGen Pharma revenue growth between 2023 and 2024 was 9%. |
| Is UroGen Pharma profitable? | Yes, UroGen Pharma is EBITDA-positive (as of the last 12 months). |
Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.
